82 related articles for article (PubMed ID: 26068800)
1. Progression and Transformation of Clonally Heterogeneous B-cell Lymphoma.
Weiss RF; Smith MR; Miller MG; Cronin JF
PLoS One; 2015; 10(6):e0130590. PubMed ID: 26068800
[TBL] [Abstract][Full Text] [Related]
2. IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution.
Mao Z; Quintanilla-Martinez L; Raffeld M; Richter M; Krugmann J; Burek C; Hartmann E; Rudiger T; Jaffe ES; Müller-Hermelink HK; Ott G; Fend F; Rosenwald A
Am J Surg Pathol; 2007 Oct; 31(10):1605-14. PubMed ID: 17895764
[TBL] [Abstract][Full Text] [Related]
3. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis.
Ghesquières H; Berger F; Felman P; Callet-Bauchu E; Bryon PA; Traverse-Glehen A; Thieblemont C; Baseggio L; Michallet AS; Coiffier B; Salles G
J Clin Oncol; 2006 Nov; 24(33):5234-41. PubMed ID: 17043351
[TBL] [Abstract][Full Text] [Related]
5. Alternate clonal dominance in richter transformation presenting as extranodal diffuse large B-cell lymphoma and synchronous classic Hodgkin lymphoma.
Di Bernardo A; Mussetti A; Aiello A; De Paoli E; Cabras AD
Am J Clin Pathol; 2014 Aug; 142(2):227-32. PubMed ID: 25015865
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
[TBL] [Abstract][Full Text] [Related]
7. Monitoring Disease Progression and Therapeutic Response in a Disseminated Tumor Model for Non-Hodgkin Lymphoma by Bioluminescence Imaging.
Köberle M; Müller K; Kamprad M; Horn F; Scholz M
Mol Imaging; 2015; 14():400-13. PubMed ID: 26218718
[TBL] [Abstract][Full Text] [Related]
8. Transformation of a previously diagnosed diffuse large B-cell lymphoma to plasmablastic lymphoma.
Marini C; Baldaia H; Trigo F; Castillo JJ
Am J Hematol; 2016 Aug; 91(8):E324. PubMed ID: 27012155
[No Abstract] [Full Text] [Related]
9. Hodgkin disease with subsequent transformation to CD30 positive non-hodgkin lymphoma in six patients.
Mori N; Watanabe K; Yamashita Y; Nakayama A; Yatabe Y; Narita M; Kobayashi T; Hasegawa Y; Kojima H; Nagasawa T
Cancer; 1999 Feb; 85(4):970-9. PubMed ID: 10091777
[TBL] [Abstract][Full Text] [Related]
10. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
[TBL] [Abstract][Full Text] [Related]
11. Pseudolymphoma evolving into diffuse large B-cell lymphoma.
Anandasabapathy N; Pulitzer M; Epstein W; Rosenman K; Latkowski JA
Dermatol Online J; 2008 May; 14(5):22. PubMed ID: 18627758
[TBL] [Abstract][Full Text] [Related]
12. Can cutaneous low-grade B-cell lymphoma transform into primary cutaneous diffuse large B-cell lymphoma? An immunohistochemical study of 82 cases.
Plaza JA; Kacerovska D; Sangueza M; Schieke S; Buonaccorsi N; Suster S; Kazakov DV
Am J Dermatopathol; 2014 Jun; 36(6):478-82. PubMed ID: 24698933
[TBL] [Abstract][Full Text] [Related]
13. Sequential development of histiocytic sarcoma and diffuse large b-cell lymphoma in a patient with a remote history of follicular lymphoma with genotypic evidence of a clonal relationship: a divergent (bilineal) neoplastic transformation of an indolent B-cell lymphoma in a single individual.
Wang E; Papalas J; Hutchinson CB; Kulbacki E; Huang Q; Sebastian S; Rehder C; Silbermins D; Moore J; Datto M
Am J Surg Pathol; 2011 Mar; 35(3):457-63. PubMed ID: 21317718
[TBL] [Abstract][Full Text] [Related]
14. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
15. Peripheral T-cell lymphoma with progression to a clonally related, Epstein Barr virus+, cytotoxic aggressive T-cell lymphoma: evidence for secondary EBV infection of an established malignant T-cell clone.
Langer R; Geissinger E; Rüdiger T; von Schilling C; Ott G; Mandl-Weber S; Quintanilla-Martinez L; Fend F
Am J Surg Pathol; 2010 Sep; 34(9):1382-7. PubMed ID: 20739840
[TBL] [Abstract][Full Text] [Related]
16. Unusual sequence of lymphoid disorders: follicular lymphoma subsequent to Hodgkin lymphoma and transformed into diffuse large B-cells non Hodgkin lymphoma.
Niscola P; Palombi M; Fratoni S; Trawinska MM; Scaramucci L; Giovannini M; Perrotti A; De Fabritiis P
Acta Oncol; 2009; 48(7):1073-4. PubMed ID: 19308758
[No Abstract] [Full Text] [Related]
17. Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective.
Sehn LH; Connors JM
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 1):26-34. PubMed ID: 15934515
[TBL] [Abstract][Full Text] [Related]
18. A cultured malignant B-1 line serves as a model for Richter's syndrome.
Peng B; Sherr DH; Mahboudi F; Hardin J; Wu YH; Sharer L; Raveché ES
J Immunol; 1994 Aug; 153(4):1869-80. PubMed ID: 8046247
[TBL] [Abstract][Full Text] [Related]
19. Richter's transformation to diffuse large B-cell lymphoma: a retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study Group.
Tadmor T; Shvidel L; Bairey O; Goldschmidt N; Ruchlemer R; Fineman R; Rahimi-Levene N; Herishanu Y; Yuklea M; Arad A; Aviv A; Polliack A;
Am J Hematol; 2014 Nov; 89(11):E218-22. PubMed ID: 25110869
[TBL] [Abstract][Full Text] [Related]
20. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies.
Friedberg JW; Neuberg D; Gribben JG; Mauch P; Anderson KC; Soiffer RJ; Takvorian T; Fisher DC; Schlossman R; Jallow H; Kuhlman C; Ritz J; Freedman AS
Biol Blood Marrow Transplant; 1999; 5(4):262-8. PubMed ID: 10465106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
